Free cash flow swung from a $273.7M outflow in 2026Q2 to a $39.5M inflow in 2025Q3 and was -$5.6M in 2026Q3, with stock-based compensation of $33.3M in the latest quarter suggesting a meaningful portion of economic cost is paid in equity rather than cash.
Mirum Pharmaceuticals, Inc. (MIRM) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | -500.02M | 55.83M | 10.32M | -70.94M | -120.14M | -132.76M | -89.08M | -39.36M | -373K |
| Operating CF Margin % | - | 10.71% | 3.06% | -38.07% | -155.9% | -693.69% | - | - | - |
| Operating CF Growth % | -13824.35% | 440.7% | 114.55% | 40.95% | 9.51% | -49.04% | -126.3% | -10452.82% | - |
| Net Income | -903.88M | -23.36M | -87.94M | -163.41M | -135.66M | -83.99M | -103.27M | -52.55M | -17.35M |
| Depreciation & Amortization | 26.77M | 24.24M | 23.63M | 10.83M | 3.24M | 975K | 623K | 324K | 4.37M |
| Stock-Based Compensation | 155.31M | 71.42M | 48.44M | 35.02M | 27.01M | 23.09M | 12.55M | 6.07M | 51K |
| Deferred Taxes | 0 | 0 | 0 | 0 | -6.58M | 595K | 72K | 0 | 0 |
| Other Non-Cash Items | 850.74M | 3.24M | 3.6M | 69.26M | 12.91M | -90.41M | 335K | -326K | 10.11M |
| Working Capital Changes | 161.18M | -19.71M | 22.59M | -22.64M | -21.05M | 16.98M | 611K | 7.12M | 2.44M |
| Change in Receivables | -71.58M | -48.05M | -11.43M | -43.97M | -20.73M | 0 | 0 | 0 | 0 |
| Change in Inventory | -6.62M | -8.45M | -3.17M | -4.39M | -3.45M | -495K | 0 | 0 | 0 |
| Change in Payables | 128.06M | 50.1M | 40.31M | 30.78M | 7.64M | 22.66M | 3.68M | 10.06M | 2.45M |
| Cash from Investing | -210.99M | -23.95M | -90.13M | -107.2M | 7.7M | 48.55M | 37.87M | -127.78M | -7.5M |
| Capital Expenditures | -13.26M | -954K | -993K | -109K | -278K | -19.02M | -225K | -281K | -7.5M |
| CapEx % of Revenue | 1.98% | 0.18% | 0.29% | 0.06% | 0.36% | 99.4% | - | - | - |
| Acquisitions | 0 | 0 | 0 | -212.76M | -7.98M | -19M | -38.1M | 127.5M | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -35M | 0 | -20M | -20M | 7.98M | 127M | 38.1M | -127.5M | -11.25M |
| Cash from Financing | 706.25M | 40.14M | 17.7M | 336.6M | 109.09M | 73.47M | 181.29M | 127.18M | 59.84M |
| Debt Issued (Net) | 135.97M | 0 | 0 | 305.3M | 0 | 0 | 0 | 0 | 50K |
| Equity Issued (Net) | 570.29M | 40.14M | 17.7M | 216.68M | 107.37M | 6.91M | 131.87M | 127.18M | 59.79M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | -185.39M | 1.72M | 66.55M | 49.42M | 0 | 0 |
| Net Change in Cash | -9.35M | 75.24M | -63.4M | 158.32M | -3.34M | -10.75M | 130.12M | -39.99M | 51.96M |
| Free Cash Flow | -503.28M | 54.87M | 9.33M | -91.05M | -120.41M | -151.78M | -89.3M | -39.64M | -7.87M |
| FCF Margin % | -75.03% | 10.53% | 2.77% | -48.85% | -156.26% | -793.09% | - | - | - |
| FCF Growth % | -1235.61% | 488.01% | 110.25% | 24.38% | 20.67% | -69.97% | -125.26% | -403.53% | - |
| FCF per Share | -7.62 | 1.09 | 0.20 | -2.23 | -3.54 | -5.01 | -3.54 | -1.72 | -0.34 |
| FCF Conversion (FCF/Net Income) | 0.56x | -2.39x | -0.12x | 0.43x | 0.89x | 1.58x | 0.86x | 0.75x | 0.02x |
| Interest Paid | 300K | 0 | 12.65M | 6.82M | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 2.15M | 0 | 1M | 125K | 0 | 0 | 11K | 21K | 0 |
Quick answers to the most common questions about buying MIRM stock.
Mirum Pharmaceuticals, Inc. (MIRM) generated $55.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Mirum Pharmaceuticals, Inc. (MIRM) generated $54.9M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Mirum Pharmaceuticals, Inc. (MIRM) spent $1.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Cash burn from operations
Metrics are mathematically derived from official filings.
Net Losses Overshadow Operating Cash Swings
Based on the reported quarterly figures, MIRM's operating cash flow swung from a $273.0M outflow in 2026Q2 to a $6.1M inflow in 2025Q4, while net income remained negative in most quarters, making the conversion ratio unreliable for judging earnings quality. The mismatch between the two suggests working capital timing, not earnings, is driving cash results.
The 2026Q1 net loss of $790.2M sits against an operating cash outflow of only $228.8M, which points to a large non-cash or one-time charge rather than operating deterioration. Conversion ratios such as OCF/NI of 4.06 in 2026Q2 are mathematically meaningful only because both figures are negative, so they should not be read as evidence of cash generation. Investors should monitor whether the reported cash outflows reflect a sustained operating burn or episodic working capital movements.
Free Cash Flow Remains Deeply Volatile
According to the reported quarterly data, MIRM's free cash flow margin ranged from -155.3% in 2026Q2 to 29.7% in 2025Q3, with the company generating positive FCF in only three of the last ten quarters. This pattern indicates cash generation has not yet stabilized into a durable trend.
The sharp move to a $273.7M FCF outflow in 2026Q2, following a brief positive quarter in 2025Q3, suggests the business is still exposed to large swings in working capital and collections. Positive FCF quarters in 2025 were small in absolute terms relative to the $185.7M quarterly revenue base, so profitability has not yet translated into consistent cash surplus. The trajectory warrants further investigation before a sustainable cash profile can be assumed.
Working Capital Drives Quarterly Cash Volatility
As reported in the financial statements, MIRM's working capital change reached $102.2M in 2026Q1 and $62.0M in 2026Q2, while several 2025 quarters showed reversals of similar magnitude, indicating receivables and payables timing dominates reported cash results.
Large working capital swings relative to operating losses suggest the cash figures are more sensitive to collection and payment timing than to underlying unit economics. The repeated sign reversals imply that quarterly OCF is poorly representative of run-rate cash generation. Investors may wish to examine receivables aging and payables terms to determine whether these movements are structural or temporary.
Minimal Capital Intensity Limits Investment Drag
Based on MIRM's reported figures, capital expenditure remained below 1% of revenue in most quarters, with the exception of a 6.7% ratio in 2026Q1 when CapEx reached $10.7M, indicating the business is asset-light.
The low capital intensity means that cash burn is driven almost entirely by operating expenses and working capital rather than by investment in physical assets. The single elevated CapEx quarter in 2026Q1 appears isolated and does not establish a trend in asset investment. Because D&A runs near $6.1M per quarter, maintenance requirements appear modest relative to the reported revenue base.
Stock-Based Compensation Masks Cash Dilution
According to the reported figures, MIRM's stock-based compensation reached $66.8M in 2026Q2 and has exceeded $13M in most recent quarters, meaning a meaningful share of economic cost is paid in equity rather than cash and may flatter the cash outflow picture.
Because SBC is added back in operating cash flow, the reported cash burn understates the full economic cost borne by shareholders through dilution. The elevated SBC relative to operating cash outflows suggests that equity issuance may be substituting for cash compensation. Investors should weigh reported FCF alongside share count growth to gauge the true cost of the operating model.